While Aducanumab has been approved by FDA, there has been a major controversy over the clinical trials conducted to test the drug. While the first showed some improvement in patients, the second failed to show any benefit. In the base case, aducanumab’s value-based price was $2000/y from a health care sector perspective and $3000/y from a societal perspective (Table 2). Regardless of the availability and eventual post-marketing outcomes of aducanumab, clinicians and researchers alike must strive to further develop and implement integrated care models for individuals with MCI and AD dementia to improve quality of life and ease the suffering and consequences of caregiving. However, the controversies surrounding the FDA approval of aducanumab are worthy of further investigation so that the public regains trust in the review process not only for the potential promise of aducanumab but, even more importantly, for the future development of desperately needed disease-modifying therapies for this epidemic of our times. To capture the short-term dynamics of treatment discontinuation,3,13 the model uses a 1-month cycle length.
We developed a Markov state‐transition model of AD to project the incremental cost‐effectiveness ratio (ICER) of aducanumab compared to standard of care (SOC) over a 5‐year time horizon for a cohort of persons aged 65 years with mild AD. The model simulates the progression of patients with mild AD to moderate and, subsequently, severe AD (Figure S1 in supporting information). Each AD disease state carries distinct costs, disability weights, and mortality rates. We projected lifetime medical costs assuming a health‐care system perspective and applied a 3% discount rate to costs and quality‐adjusted life years (QALYs). 4
We interpreted ICERs using a willingness‐to‐pay (WTP) threshold of $100,000/QALY gained. We found that an indefinitely dosed treatment would not warrant a price of greater than $50 000/y, as was initially proposed for aducanumab, even if it slowed disease progression by 90%.
- As such, we incorporated data that would skew toward the cost‐effectiveness of aducanumab and accounted for uncertainty using both deterministic and probabilistic sensitivity analyses.
- The hallmark of Alzheimer’s disease is the accumulation of the debris caused by the breakdown of neurons in the brain, leading to plaque formation.
- The annual cost of $50,000 for aducanumab that has been suggested by market analysts would not be commensurate with its clinical benefits.
- On 7 June 2021, the US FDA approved aducanumab, a human IgG1 anti-Aβ monoclonal antibody selective for Aβ aggregates, as the first disease-modifying treatment for AD.
- In one‐way deterministic sensitivity analysis, the two parameters with the greatest impact on the ICER were the time horizon and the cost of aducanumab (Figure S2 in supporting information).
“The $56,000 price for aducanumab is a rational manufacturer response to an irrational insurance system. If the United States does not wish to face similarly high prices for each new pharmaceutical product, it must address the inflationary incentives inherent in Medicare’s reimbursement formula, the method of drug distribution for infused drugs, and the structure of consumer cost-sharing,” Robinson concluded. Donanemab, on the other hand, is administered once a month and is stopped once patients reach a certain threshold for amyloid levels. The 35% slower cognitive decline is measured using a scale called integrated Alzheimer’s Disease Rating Scale (iADRS).
Biogen cuts the price tag on its Alzheimer’s drug in half
More broadly, we recognize that incremental cost-effectiveness is not the only means of defining a treatment’s value; factors such as scientific advances spurred by novel treatments66 or the hope offered to patients with terminal illness67 were not incorporated into our analysis, but could reasonably inform the decisions of patients, clinicians, and policy makers. To address this challenge, we developed a decision-analytic model of AD treatment, incorporating published data on AD natural history, its health care and societal costs, and the efficacy and adverse effects of anti–amyloid antibody treatments. We used this model to evaluate the cost-effectiveness of aducanumab and donanemab for early AD in the US, and to estimate prices at which these agents would become cost-effective.
It is to be noted that these trials were conducted on patients who were in the early stages of the disease,” a researcher from the Centre for Brain Research, Indian Institute of Science, Bengaluru told The Indian Express. Despite not enough evidence, the drug was approved by the FDA under narrow clinical circumstances. It is for people with early-stage Alzheimer’s who have had a PET scan confirming the presence of beta-amyloid in their brain. The hallmark aducanumab price in india of Alzheimer’s disease is the accumulation of the debris caused by the breakdown of neurons in the brain, leading to plaque formation. The drug aducanumab, with brand name Aduhelm, is a monoclonal antibody that is designed to reduce the presence of amyloid beta, a protein that forms plaques in the brain. Developed by Biogen, the drug named Aducanumab is said to slow down the progression of Alzheimer’s disease that affects the functioning of the brain.
Some states, such as Massachusetts and Tennessee, have requested waivers and adjustments from CMS to offset this possibility, for now, the responsibility remains at hand. Aducanumab’s (Aduhelm; Biogen) $56,000 price point reflects the larger challenges of the United States’ insurance system and incites a cyclical series of events that have repercussions on cost of future therapies, state budgets, and legislative decisions. Other than that, doctors suggest that people, especially the elderly and those with family history, should keep their brains active and engaged.
Information about Aducanumab
The approval will bring massive financial gains for Biogen, which saw its shares gain 38 per cent after the nod to its drug. The company has said that it would charge an average of $56,000 a year per patient to use the drug which is going to be one of the best-selling pharmaceutical products in the world. Alzheimer’s disease is the most common form of dementia and contributes per cent of the cases. According to the World Health Organisation (WHO), it is a syndrome in which there is deterioration in memory, thinking, behaviour and the ability to perform everyday activities. The agency said about half of that hike was due to the need for a contingency fund to cover Aduhelm.
Declare live-in relationship or face up to 6 months jail: Uttarakhand Civil Code
Additional challenges in providing care would be issues regarding payments for treatments, regulatory changes, workforce expansion, and planning and coordination of care both at the national and local levels along with awareness campaigns. The analysis also states that no individual stakeholder will be able to coordinate the care needs of all individuals with AD. The report recommends starting timely collaborations between the stakeholders to address all obstacles in providing care to individuals with AD.
The drug is the first since 2003 to attack the biological underpinnings of the disease, instead of just postponing the symptoms. The disease, categorised in three stages, is identified with symptoms such as forgetfulness, losing track of time, having increasing difficulty with communication, difficulty in recognising faces and experiencing behaviour changes that may escalate and include aggression. Dementia is one of the major causes of disability and dependencies among older people worldwide. The disease has a physical, psychological, social, and economic impact not only on people who are suffering from it but also on immediate families. Unlike the federal government, states can’t run budget deficits, which means they would have to raise taxes or reduce spending in other areas to pay for aducanumab,” Sachs and Bagley wrote, drawing parallels to a prior instance of such a restriction in the case of hepatitis C therapy sofosbuvir (Sovaldi; Gilead).
Importance
Several anti–amyloid monoclonal antibodies have been developed for slowing the progression of Alzheimer disease (AD). Among the furthest developed are aducanumab, which received accelerated approval from the US Food and Drug Administration in 2021, and donanemab, which is currently undergoing phase 3 trials. In a critical appraisal of monoclonal antibody therapies that target Aβ plaque formation and removal in AD, Decourt et al. indicate that lecanemab, solanezumab, crenezumab, donanemab, and ganterenumab are being studied in individuals with AD.27 Although these drugs are relatively safe for use in humans, they have had limited positive outcomes in the clinical trials.
This decision of the FDA has become controversial with experts saying that clinical trials of the drug had returned unsatisfactory. Now, the consecutive success of three therapies in two years in slowing cognitive decline in patients with early Alzheimer’s establishes more firmly the https://1investing.in/ theory that one of the main causes of the disease are the abnormal clumps of amyloid beta protein around brain cells. Donanemab is a monoclonal antibody that targets the abnormal plaques of amyloid beta protein characteristically seen in brain images of those with Alzheimer’s.
The statistical review and evaluation of aducanumab by the FDA stated that the available data did not seem to provide sufficient evidence to support the efficacy of high-dose aducanumab amongst individuals with AD.10 The reviewers noted several issues with the trial data regarding aducanumab. (1) Both studies were terminated early for futility and were not fully completed, with the data cut-off date being 26 December 2018 and the public futility announcement date being 21 March 2019. (2) There was sporadic unblinding for dose management of ARIA cases, which was noted to be much higher in the drug-treated group.
Aduhelm (aducanumab) aims at altering the course of the disease by slowing the deterioration of brain function. Consent was not necessary for this modeling study which did not make use of human subject data. All tau PET assessments performed in the placebo-controlled period were pooled from Study 301 and 302 and used as one postbaseline timepoint.
In conclusion, our model suggests that aducanumab is likely not cost‐effective at an annual price of $56,000. Aducanumab was recently approved by the Food and Drug Administration despite the lack of clinical effectiveness data. The newly developed drug is likely to overshadow the five medicines previously approved to treat the brain condition in one way or the other. The existing drugs to treat Alzheimer’s disease are Aricept, Razadyne, Exelon, Namenda and Namzaric.
With each cycle, patients have a stage-specific probability of progression to the next disease stage; every 12 cycles, all patients progress to the next age. Each stage has a unique health care cost, additional societal cost, utility, and mortality hazard ratio (HR). Model states are represented by boxes; transitions between states are represented by arrows. Patients in each clinical stage have a monthly probability of transition to the next stage, denoted by rn; when receiving anti–amyloid antibody treatment, this probability is increased or decreased according to the efficacy of the treatment, denoted by H. Patients in all states are subject to an age- and stage-specific mortality probability; for clarity, these arrows are omitted from the diagram. Every 12 months, all surviving patients transition to the next age category, as represented by the horizontal arrows.
The company said it was cutting costs in part because the slow debut of Aduhem was affecting its revenue. Doctors have said concerns over the price were compounded by costs patients also would face for regular testing and scans needed to monitor their progress on Aduhelm. But Aduhelm’s debut has been slowed by concerns over the price and research behind the drug. Some insurers have balked at paying for the drug, while medical centers across the country have been either slow to decide on using the drug or said they weren’t planning to prescribe it for now. Biogen CEO Michel Vounatsos said in a prepared statement that too many patients were not being offered the drug due to “financial considerations,” and their disease had progressed beyond the point where Aduhelm could help.